Structural effects of hypermodified nucleosides in the Escherichia coli and human tRNALys anticodon loop: the effect of nucleosides s2U, mcm5U, mcm5s2U, mnm5s2U, t6A, and ms2t6A.
Previous nuclear magnetic resonance (NMR) studies of unmodified and pseudouridine39-modified tRNA(Lys) anticodon stem loops (ASLs) show that significant structural rearrangements must occur to attain a canonical anticodon loop conformation. The Escherichia coli tRNA(Lys) modifications mnm(5)s(2)U34 and t(6)A37 have indeed been shown to remodel the anticodon loop, although significant dynamic flexibility remains within the weakly stacked U35 and U36 anticodon residues. The present study examines the individual effects of mnm(5)s(2)U34, s(2)U34, t(6)A37, and Mg(2+) on tRNA(Lys) ASLs to decipher how the E. coli modifications accomplish the noncanonical to canonical structural transition. We also investigated the effects of the corresponding human tRNA(Lys,3) versions of the E. coli modifications, using NMR to analyze tRNA ASLs containing the nucleosides mcm(5)U34, mcm(5)s(2)U34, and ms(2)t(6)A37. The human wobble modification has a less dramatic loop remodeling effect, presumably because of the absence of a positive charge on the mcm(5) side chain. Nonspecific magnesium effects appear to play an important role in promoting anticodon stacking. Paradoxically, both t(6)A37 and ms(2)t(6)A37 actually decrease anticodon stacking compared to A37 by promoting U36 bulging. Rather than stack with U36, the t(6)A37 nucleotide in the free tRNAs is prepositioned to form a cross-strand stack with the first codon nucleotide as seen in the recent crystal structures of tRNA(Lys) ASLs bound to the 30S ribosomal subunit. Wobble modifications, t(6)A37, and magnesium each make unique contributions toward promoting canonical tRNA structure in the fundamentally dynamic tRNA(Lys)(UUU) anticodon.
Durant
Philippe C
PC
Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, USA.
Bajji
Ashok C
AC
Sundaram
Mallikarjun
M
Kumar
Raju K
RK
Davis
Darrell R
DR
D000241:Adenosine / Q000031:analogs & derivatives* / Q000737:chemistry; D000926:Anticodon / Q000737:chemistry*; D020029:Base Pairing; D001665:Binding Sites / Q000235:genetics; D003062:Codon / Q000737:chemistry; D004926:Escherichia coli / Q000235:genetics*; D005818:Genetic Engineering; D006801:Humans; D008274:Magnesium / Q000737:chemistry; D008958:Models, Molecular; D019906:Nuclear Magnetic Resonance, Biomolecular; D009690:Nucleic Acid Conformation; D011560:Pseudouridine / Q000737:chemistry; D012357:RNA, Transfer, Lys / Q000737:chemistry*; D012270:Ribosomes / Q000737:chemistry; D013816:Thermodynamics; D013872:Thionucleosides / Q000737:chemistry*; D013891:Thiouridine / Q000031:analogs & derivatives* / Q000737:chemistry
C105273:2-thiouridine; D000926:Anticodon; D003062:Codon; D012357:RNA, Transfer, Lys; D013872:Thionucleosides; D013891:Thiouridine; D011560:Pseudouridine; C003268:N(6)-(N-threonylcarbonyl)adenosine; C011916:5-methylaminomethyl-2-thiouridine; C031691:N-((9-beta-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine; C030546:5-(carboxymethylaminomethyl)-2-thiouridine; D008274:Magnesium; D000241:Adenosine